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Abstract 
Introduction: The pathology mechanism of subclinical hypothyroidism and subclinical hypothyroidism complicated with type 2 diabetes 
remained uncertain. We aimed to find potential related long non-coding RNAs (lncRNAs) and mRNAs in the above diseases.
Material and methods: Transcriptome sequencing was performed in three patients with subclinical hypothyroidism (S), three patients 
with subclinical hypothyroidism complicated with type 2 diabetes (SD), and three healthy controls (N). Differentially expressed mRNAs 
(DEmRNAs) and differentially expressed lncRNAs (DElncRNAs) were screened in S vs. N, SD vs. N, and SD vs. S group, and the nearby 
and co-expressed DEmRNAs of DElncRNAs were screened in S vs. N and SD vs. N. Moreover, functional analysis of DEmRNAs was then 
performed by Metascape. 
Results: In total, 465, 1058, and 943 DEmRNAs were obtained in S vs. N, SD vs. N, SD vs. S, respectively, and 191 overlapping genes were 
obtained in S vs. N and SD vs. N group. Among which, LAIR2, PNMA6A, and SFRP2 were deduced to be involved in subclinical hypo-
thyroidism, and GPR162, APOL4, and ANK1 were deduced to be associated with subclinical hypothyroidism complicated with type 2 
diabetes. A total of 50, 100, and 88 DElncRNAs were obtained in S vs. N, SD vs. N and SD vs. S, respectively. Combining with the interac-
tion network of DElncRNA-DEmRNA, PAX8-AS1, co-expressed with KIR3DL1, was identified to function in subclinical hypothyroidism, 
and JHDM1D-AS1, co-expressed with ANK1, was deduced to play a role in subclinical hypothyroidism complicated with type 2 diabetes. 
Conclusions: Dysfunctional lncRNAs and mRNAs may be involved in the development of subclinical hypothyroidism and subclinical 
hypothyroidism complicated with type 2 diabetes. (Endokrynol Pol 2020; 71 (3): 213–226)
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Introduction
Hypothyroidism, as a result of insufficient thyroid hor-
mone secretion, leads to a decline in the body’s meta-
bolic activity and other clinical syndromes [1]. Clinical 
hypothyroidism and subclinical hypothyroidism (SCH) 
were identified according to the degree of thyroid 
function reduction. SCH was biochemically defined 
as an elevated serum thyroid stimulating hormone 
(TSH) level, whereas the stable serum free T4 level was 
within the population reference range. Patients with 
SCH varied among populations and ranged from 3% to 
15%, with a higher incidence associated with increasing 
age, female sex, and suboptimal iodine status [2]. The 
SCH was distinguished by the degree of TSH in clinical 
diagnosis. TSH normal laboratory reference range was 
0.3–5.0 mIU/L, and higher than 5 mIU/L was regarded 
as SCH [2–5]. However, the TSH range defining SCH 
remained elusive [3], and few molecular mechanisms 
were investigated in subclinical hypothyroidism. There-
fore, a large number of researchers devoted time to the 
discovery biomarkers and molecular characters in SCH.
Although many patients with SCH were asymp-
tomatic, some studies have shown a close relationship 
between SCH and several diseases, including heart 
failure [6], depression [7], atherosclerosis [8], as well 
as abortion [9]. It is reported that the prevalence of 
hypothyroidism in diabetics varies from 0.2% to 1.7% 
[10]. However, a cross-sectional study showed that the 
prevalence of SCH was similar between patients with 
diabetes mellitus and healthy controls [11]. Therefore, 
we analysed molecular characters in patients with SCH 
(S), patients with SCH complicated with type 2 diabe-
tes (SD), and healthy controls (N) by transcriptome 
sequencing to explore whether type 2 diabetes was 
associated with SCH.  
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clinical information of all these participants is shown in Table 1. In 
addition, statistical analysis of tobacco smoking, alcohol drinking, 
diet, and medicaments in SD and S compared with controls are 
shown in supplementary Table S1 and supplementary Table S2, 
respectively. There was no significant difference in terms of the 
above clinical index in SD and S compared with controls. A whole 
blood sample (2.5 mL per BD tube) for RNA-Seq was taken from the 
cubital vein of the arm at room temperature. Then, the blood sample 
was inverted slowly for mixture 8–10 times. After vertical placement 
at 18–25∞C for three days, the blood samples were stored at 2–8∞C 
for five days, then at –20∞C for 24 hours, and finally transferred to 
–80∞C for long-term storage (50 months).
This study was approved by the Ethics Committee of Jinan Central 
Hospital (Series number: 2018-103). Signed informed consent was 
obtained from all the participants. This research complied with the 
principles of the Declaration of Helsinki.
RNA isolation, library construction, 
and sequencing
Total RNA was extracted from blood samples by using by TRIzol 
reagent (Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. A Nanodrop ND-2000 spectrophotometer 
(Thermo Scientific, Wilmington, DE, USA) and 2% agarose gel were 
used to check the concentration and purity of RNA. An Agilent 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA) was used to obtain 
the RIN (RNA integrity number) value (from 0 to 10). The larger the 
value, the better and more complete the RNA. Only RNA samples 
with RIN > 7 can be used for RNA sequencing.
A library for high-throughput sequencing of lncRNA and mRNA 
was constructed by qualified RNA. Firstly, we removed the ribosomal 
RNA from total RNA and then randomly fragmented RNA into 
about 200 base pairs. Secondly, the first cDNA strand was synthe-
sised by RNA fragments primed with random hexamer primers, and 
then the second cDNA strand was synthesised with dUTP instead 
of dTTP. Finally, after purification by the Qiaquick PCR purification 
kit, end repair, 3’ end adenylation, adapter ligation, UNG digestion, 
polymerase chain reaction (PCR), and gel extraction, the library 
construction was completed. The cDNA library was qualified by 
an Agilent 2100 Bioanalyzer and ABI StepOnePlus Real-TimePCR 
System and then sequenced by Illumina Hiseq x-ten machine.
Quality control of raw data and clean-reads 
mapping
Clean reads were obtained from the raw reads by removing low-
quality sequences (< Q20) and shorter sequences < 20 bp and 
ambiguous ‘N’ nucleotides (with the ratio of ‘N’ > 10%) using 
Long non-coding RNAs (lncRNAs) are defined as 
a heterogeneous class of non-coding transcripts > 200 
base pairs in length [12, 13]. It has been demonstrated 
that lncRNAs plays key roles in the regulation of mRNA 
splicing, transcription, translation, import, export and 
stability [14]. In view of the important roles of lncRNAs, 
we aimed to identify the key mRNA, lncRNA, and 
mRNA-lncRNA co-expressed pairs, and performed 
functional enrichment analysis to reveal the patho-
genesis of SCH and SCH complicated with type 2 dia-
betes. Our study may be helpful in understanding the 
molecular changes of identified lncRNAs and mRNAs 
in SCH and SCH complicated with diabetes. 
Material and methods
Subjects and blood sampling
Study samples consisted of three patients with subclinical hypothy-
roidism (S), three patients with subclinical hypothyroidism compli-
cated with type 2 diabetes (SD), and three healthy control subjects 
(N). The inclusion criteria of subclinical hypothyroidism were as 
follows: TSH > 4.0 mIU/L, and normal serum free triiodothyronine 
FT3 and free thyroxine FT4 levels. The exclusion criteria of subclini-
cal hypothyroidism were as follows: no intermittent claudication; 
refractory ulcers and gangrene of lower extremities; type 1 diabetes; 
acute complications of diabetes; cardiac insufficiency; severe infec-
tion; severe liver and kidney disease; malignant tumours; previous 
history of thyroid disease; history of blood transfusion in the past six 
months; and pregnant or lactating patients. The inclusion criteria of 
subclinical hypothyroidism complicated with type 2 diabetes were 
as follows: TSH > 4.0 mIU/L; normal serum free triiodothyronine 
(FT3) and free thyroxine (FT4) levels; and type 2 diabetes. The exclu-
sion criteria of subclinical hypothyroidism complicated with type 
2 diabetes were as follows: no intermittent claudication; refractory 
ulcers and gangrene of lower extremities; cardiac insufficiency; se-
vere infection; severe liver and kidney disease; malignant tumours; 
previous history of thyroid disease; history of blood transfusion in 
the past six months; and pregnant or lactating patients. The inclusion 
criteria of the healthy population control group were as follows: age 
as close as possible to the patients in the disease group; no history 
of thyroid disease; and no history of type 2 diabetes. In addition to 
the correct diagnosis, the interview provided information including 
all participates’ age, gender, TSH value, and family history. Detailed 
Table 1. Clinical information of participants
Group Number Gender Age [year] Weight [kg]
TSH 
[mIU/L]
FT3 
[pmol/L]
FT4 
[pmol/L]
FBG 
[mmol/L]
Family 
history
S
1 Female 56 65 5.61 4.88 16.25 5.6 No
2 Female 61 70 5.06 4.54 14.5 5 No
3 Male 58 65 17.3 4.74 12.07 5.1 No
SD
1 Female 49 59 7.01 4.05 14.96 8.5 No
2 Male 60 78 6.54 4.37 15.1 8.1 No
3 Male 56 90 7.39 4.92 19.66 8.8 No
Control
1 Female 46 64 1.4 3.8 15.5 5.3 No
2 Male 48 79.7 1.16 5.82 19.93 4.6 No
3 Female 46 64 0.56 4.32 15.11 4.8 No
S — subclinical hypothyroidism; SD — subclinical hypothyroidism complicated with diabetes; TSH — thyroid-stimulating hormone; FT3— free triiodothyronine;  
FT4 — free thyroxine; FBG — fasting blood glucose
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Cutadapt software (http://cutadapt.readthedocs.io). After trimming, 
the high-quality clean reads were aligned with the human refer-
ence genome GRCh38 by TopHat (http://tophat.cbcb.umd.edu/), 
which can be downloaded in NCBI, UCSC, RefSeq, and Ensembl.
Identification of differentially expressed mRNAs 
and lncRNAs
Expression quantitation and standardised output were performed 
by Cuffquan. Differentially expressed mRNAs and lncRNAs be-
tween patients with different diseases and healthy persons (S vs. N, 
SD vs. N and S vs. SD) were identified by Cuffdiff (http://cufflinks.
cbcb.umd.edu/) (p value < 0.05). In addition, shared genes were 
identified in the intersection of the S and SD groups.
Identification of cis-regulated mRNAs  
and co-expressed mRNAs of lncRNAs  
In order to explore the cis-regulated mechanism of lncRNAs, the 
nearby mRNAs were identified within a 100 kb window up- or 
down-stream of DElncRNAs in S vs. N and S vs. N groups. More-
over, the correlation between DElncRNA and DEmRNA in the two 
groups (S vs. N, SD vs. N) was analysed by Pearson correlation 
coefficient. The DElncRNA-DEmRNA pairs were obtained when 
|r| > 0.95 and p < 0.05, and the DElncRNA-DEmRNA interac-
tion network was then constructed by Cytoscape (http://www.
cytoscape.org/). 
Functional analysis of differentially expressed 
mRNAs and mRNA-lncRNA co-expressed pairs
Gene ontology (GO) and Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) molecular pathway enrichment analysis of 
DEmRNAs and mRNA-lncRNA co-expressed pairs in three groups 
(S vs. N, SD vs. N and SD vs. S) were performed by Metascape 
(http://metascape.org/gp/index.html) under the threshold of p-
value < 0.05. 
Results
Transcriptome sequencing, filtering, 
and annotation
After removing the low-quality reads, 6.74 × 107, 
6.96 × 107, and 6.82 × 107 reads were obtained in three 
hypothyroidism samples (S), 6.72 × 107, 6.80 × 107, and 
6.67 × 107 reads were obtained in three type 2 diabetes 
and concomitant hypothyroidism samples (SD), and 
6.75 × 107, 6.77 × 107, and 6.85 × 107 reads were obtained 
in three healthy samples (N) (Tab. 2). All of the clean 
reads were aligned with the human reference genome 
GRCh38. The concordant pair rates of all samples were 
above 78%. 
Identification of DEmRNAs and DElncRNAs
Compared to healthy controls, 465 DEmRNAs (240 
up-regulated and 225 down-regulated) were identified 
in the S group (p < 0.05). The top 20 DEmRNAs between 
S and N are shown in Table 3. Hierarchical clustering of 
the top 100 DEmRNAs between S and N is shown in Fig-
ure 1A. Compared to healthy controls, 1058 DEmRNAs 
(874 up-regulated and 184 down-regulated) were identi-
fied in the SD group (p < 0.05). The top 20 DEmRNAs 
between SD and N are shown in Table 4. Hierarchical 
clustering of the top 100 DEmRNAs between SD and 
N is shown in Figure 1B. Compared to the S group, 943 
DEmRNA (797 up-regulated and 146 down-regulated) 
were identified in the SD group (p < 0.05). The top 20 
DEmRNAs between SD and S are shown in Table 5. In 
addition, the intersection of two groups (S vs. N, SD 
vs. N) of DEmRNAs was performed by Venn diagrams 
(Fig. 2). 274 S-specific DEmRNAs, 867 SD-specific DEm-
RNAs, and 191 overlapping DEmRNAs were identified. 
Compared to healthy controls, 50 DElncRNAs (25 
up-regulated and 25 down-regulated) were identi-
fied in the S group (p < 0.05). The top 20 DElncRNAs 
between S and N are shown in Table 6. Hierarchical 
clustering of the top 100 DElncRNAs between S and N is 
shown in Figure 3A. Compared to healthy controls, 100 
DElncRNAs (83 up-regulated and 17 down-regulated) 
were identified in the SD group (p < 0.05). The top 20 
DElncRNAs between SD and N are shown in Table 7. 
Hierarchical clustering of the top 100 DElncRNAs 
between SD and N is shown in Figure 3B. Compared 
to the S group, 88 DElncRNAs (70 up-regulated and 
18 down-regulated) were identified in the SD group 
(Tab. 8). The top 20 DElncRNAs between SD and S are 
shown in Table 6. 
Table 2. Clean reads and genome mapping
Sample Clean reads Q20 (%) GC (%) Aligned pairs Concordant pair Concordant pair rate
S 67,426,220 96.06% 51.32% 28750021 28291823 83.80%
S 69,617,720 96.61% 52.25% 28229932 27718166 81.90%
S 68,231,638 96.21% 53.48% 28004235 27437375 80.10%
SD 67,226,002 96.68% 50.37% 27563225 26914177 79.80%
SD 68,029,786 96.39% 49.37% 29097641 28719125 82.50%
SD 66,704,268 96.69% 51.02% 28100877 26768940 78.50%
Control 67,539,910 97.01% 51.13% 28121092 27631140 82.20%
Control 67,726,216 96.57% 49.26% 28249243 27775680 81.70%
Control 68,480,746 95.96% 47.46% 27944572 27439744 82.30%
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Table 3. Top 20 significantly differentially expressed mRNAs in S vs. N group
Gene Locus Log2 (fold change) p value Up/Down
ARHGEF10 chr8:1823975-1958641 –3.03847 5.00E-05 Down
SLC2A14 chr12:7812511-7891196 –2.41504 5.00E-05 Down
HDC chr15:50241944-50266049 –2.3321 5.00E-05 Down
GATA2 chr3:128479421-128503207 –2.23534 5.00E-05 Down
MZB1 chr5:139387567-139389916 –1.70994 5.00E-05 Down
SLC45A3 chr1:205657850-205690435 –1.68527 5.00E-05 Down
HRH4 chr18:24460567-24487427 –1.56157 5.00E-05 Down
TMTC1 chr12:29500812-29784759 –1.39185 5.00E-05 Down
SLC4A10 chr2:161624334-161985276 –1.27193 5.00E-05 Down
BATF2 chr11:64987944-64997045 –1.21358 5.00E-05 Down
KIR2DL1 chr19:54769207-54784326 1.50381 5.00E-05 Up
KIR3DL2 chr19:54850318-54867215 1.54403 5.00E-05 Up
KIR2DL3 chr19:54738508-54753052 1.55242 5.00E-05 Up
NINL chr20:25452696-25585531 1.57776 5.00E-05 Up
KIR2DS4 chr19:54832675-54848569 1.7037 5.00E-05 Up
LAIR2 chr19:54502796-54510693 1.94618 5.00E-05 Up
KIR3DL1 chr19:54816437-54830778 1.96698 5.00E-05 Up
KLRC2 chr12:10430598-10435993 2.38573 5.00E-05 Up
RAP1GAP chr1:21596214-21669444 3.10314 5.00E-05 Up
C4BPA chr1:207104231-207159509 3.73471 5.00E-05 Up
Figure 1. Hierarchical clustering analysis of top 100 DEmRNAs between S and normal samples (A), SD and normal samples (B). Row 
and column represented DEmRNAs and samples, respectively. JJ: S group; JT: SD group
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Table 4. Top 20 significantly differentially expressed mRNAs in SD vs. N group
Gene Locus Log2 (fold change) p value Up/Down
KLRC2 chr12:10430598-10435993 3.54759 5.00E-05 Up
KRT1 chr12:52674735-52680407 3.46571 5.00E-05 Up
APOL4 chr22:36189127-36204833 3.1522 5.00E-05 Up
RAP1GAP chr1:21596214-21669444 2.82506 5.00E-05 Up
ANKRD22 chr10:88802729-88851975 2.45375 5.00E-05 Up
ARHGEF37 chr5:149552048-149634968 2.33351 5.00E-05 Up
FAM157A chr3:198152154-198198958 2.11608 5.00E-05 Up
FAM46C chr1:117605981-117628389 1.97119 5.00E-05 Up
ANK1 chr8:41653224-41896762 1.9512 5.00E-05 Up
SFRP2 chr4:153780589-153789076 1.9425 5.00E-05 Up
IFI6 chr1:27666060-27672213 –0.85871 5.00E-05 Down
CD79B chr17:63928737-63932344 –0.94624 5.00E-05 Down
IFIT1 chr10:89392545-89406487 –1.01546 5.00E-05 Down
CD79A chr19:41877119-41881372 –1.03601 5.00E-05 Down
RPS28 chr19:8321499-8322396 –1.07535 5.00E-05 Down
GPR162 chr12:6821796-6827418 –1.26035 5.00E-05 Down
TCL1A chr14:95694159-95714196 –1.54492 5.00E-05 Down
MYOM2 chr8:2045042-2145456 –1.57458 5.00E-05 Down
SLC4A10 chr2:161624334-161985276 –1.72178 5.00E-05 Down
LOC100130520 chr17:74557228-74567512 –1.85946 5.00E-05 Down
Table 5. Top 20 significantly differentially expressed mRNAs in SD vs. S group
Gene Locus Log2 (fold change) p value Up/Down
LOC100130520 chr17:74557228-74567512 –1.99776 5.00E-05 Down
LAIR2 chr19:54502796-54510693 –1.71188 5.00E-05 Down
GPR162 chr12:6821796-6827418 –1.52603 5.00E-05 Down
ZNF683 chr1:26361631-26374520 –1.40167 5.00E-05 Down
RPL26 chr17:8377515-8383247 –1.39417 5.00E-05 Down
TCL1A chr14:95694159-95714196 –1.18088 5.00E-05 Down
RPS26 chr12:56041901-56044223 –1.14595 5.00E-05 Down
RPS3A chr4:151099572-151104652 –1.05839 5.00E-05 Down
SH2D1B chr1:162395265-162412138 –1.0006 5.00E-05 Down
RPS28 chr19:8321499-8322396 –0.9618 5.00E-05 Down
PNMA6A chrX:153072413-153075019 3.89001 5.00E-05 Up
IL31RA chr5:55840333-55922854 3.47808 5.00E-05 Up
HDC chr15:50241944-50266049 3.07157 5.00E-05 Up
ANKRD22 chr10:88802729-88851975 2.85326 5.00E-05 Up
APOL4 chr22:36189127-36204833 2.66818 5.00E-05 Up
TTC26 chr7:139133743-139191986 2.42405 5.00E-05 Up
KRT1 chr12:52674735-52680407 2.38486 5.00E-05 Up
SLC2A14 chr12:7812511-7891196 2.37518 5.00E-05 Up
BATF2 chr11:64987944-64997045 2.22325 5.00E-05 Up
LOC100996713 chr1:143874742-143885954 2.21011 5.00E-05 Up
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Gene classification according to expression level
In order to clarify the expression pattern of key genes 
in three groups (S vs. N, SD vs. N, overlapping group 
and SD vs. S), we classified these genes into four groups 
according to the expression pattern: genes which sig-
nificantly different expressed in S vs. N and SD vs. N 
but showed no different expression in SD vs. S group; 
genes which significantly different expressed in S vs. N 
and SD vs. N and showed significantly different expres-
sion in SD vs. S group; genes which showed different 
expression in S vs. N and SD vs. S group; genes which 
showed different expression in SD vs. N and SD vs. S 
group (Tab. 9).
Identification of the nearby and co-expressed 
DEmRNAs of DElncRNAs
Two DElncRNA-nearby targeted DEmRNA pairs 
(involved two DElncRNAs and two DEmRNAs) and 
three DElncRNA-nearby targeted DEmRNA pairs 
(involved three DElncRNAs and three DEmRNAs) 
were obtained in the S vs. N and SD vs. N group, 
respectively (Tab. 10). In addition, a total of 336 ln-
cRNA-mRNA co-expression pairs were obtained in S 
vs. N group (|r| > 0.95 and p < 0.05). The interaction 
network of lncRNAs and mRNAs in the S vs. N group 
(Fig. 1A) showed that the LOC105369772 (degree = 56), 
LOC105369315 (degree = 32), LOC105369228 (de-
gree = 21), and LIN00235 (degree = 21) were hub 
DElncRNAs with higher degree. Meanwhile, 2536 
lncRNA-mRNA co-expression pairs were obtained 
in the SD vs. N group (|r| > 0.95 and p < 0.05). The 
interaction network of lncRNA-mRNA in the SD 
vs. N group (Fig. 1B) showed that the LOC102723540 
(degree = 96), LOC105371058 (degree = 93), and 
LOC105377826 (degree = 87) were hub DElncRNAs 
with higher degree. Several key DElncRNA-DEmRNAs 
were shared in both the S vs. N group and the SD vs. N 
S vs. N DEmRNA SD vs. N DEmRNA
274 
(20.6%)
191 
(14.3%)
867 
(65.1%)
Figure 2. Venn diagram of DEGs between S vs. N and SD vs. N. 
The purple circle represents the DEGs of S vs. N. The yellow circle 
represents DEGs of SD vs. N
Table 6. Top 20 significantly differentially expressed lncRNAs in S vs. N group
Gene Locus Log2 (fold change) p value Up/Down
PSMD5-AS1 chr9:120843041-120854373 –1.85303 5.00E-05 Down
LOC105369772 chr12:52625675-52630770 1.8639 5.00E-05 Up
LOC101929866 chr20:45178476-45191638 0.712603 0.0004 Up
LINC01002 chr19:197015-202209 –0.97745 5.00E-05 Down
LOC105369645 chr12:8563194-8566073 0.770123 0.00055 Up
LOC102725068 chr6:31479917-31494794 –0.89235 0.0009 Down
LINC01279 chr3:112596793-112601969 –1.25572 0.0012 Down
FLVCR1-AS1 chr1:212856603-212858138 –1.26572 0.00225 Down
PAX8-AS1 chr2:113215996-113278950 –0.92159 0.00265 Down
LOC101928906 chr9:41649583-41654873 1.03736 0.0006 Up
LOC105374445 chr4:48269971-48288953 5.42782 0.0008 Up
LOC101929506 chr10:79666864-79679237 –0.61574 0.00315 Down
LOC105371058 chr16:3077271-3087993 1.07842 0.00085 Up
LOC100499194 chr2:113977668-114007310 1.20659 0.00095 Up
LOC105377997 chr6:127663345-127685373 –0.88753 0.0053 Down
LINC00211 chr2:37826246-37875863 0.931827 0.0017 Up
SNHG11 chr20:38446653-38450921 2.3711 0.00245 Up
LOC101927759 chr6:3024790-3027424 –0.92149 0.00935 Down
GLIDR chr9:39803495-39810159 1.00066 0.00945 Up
LOC105378122 chr6:167111806-167139141 –0.91848 0.01145 Down
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Table 7. Top 20 significantly differentially expressed lncRNAs in SD vs. N group
Gene Locus Log2 (fold change) p value Up/Down
LOC105374150 chr3:148439991-148465791 2.10165 5.00E-05 Up
LOC105369772 chr12:52625675-52630770 1.72697 5.00E-05 Up
LOC729737 chr1:91168-267354 1.43622 5.00E-05 Up
LOC100499194 chr2:113977668-114007310 1.42705 5.00E-05 Up
JHDM1D-AS1 chr7:140177260-140179640 1.32196 5.00E-05 Up
LOC105372321 chr19:21444103-21464331 1.96597 0.00015 Up
LOC100190986 chr16:21432002-21434455 0.737839 0.00015 Up
LOC100507616 chr12:92466439-92488106 –1.16349 0.00015 Down
LOC100133331 chr1:722045-730351 1.12216 0.00035 Up
LOC102723373 chr16:53373492-53384259 –1.27737 0.00035 Down
LOC105370651 chr14:97705988-97802275 1.0367 0.00045 Up
PSMD5-AS1 chr9:120843041-120854373 –0.86208 0.00075 Down
LOC105372991 chr22:30447958-30472047 1.96689 0.00105 Up
LOC105369315 chr11:59084936-59106688 –0.94107 0.0017 Down
FLVCR1-AS1 chr1:212856603-212858138 –1.41027 0.0025 Down
LOC105375754 chr8:127664538-127670992 –0.84974 0.00655 Down
PAX8-AS1 chr2:113215996-113278950 –0.81792 0.0067 Down
LOC105377782 chr8:2199669-2206204 –1.116 0.0085 Down
LOC389641 chr8:23225220-23230926 –1.05705 0.00935 Down
LOC102723540 chr19:34850668-34860576 –1.36983 0.00955 Down
Figure 3. Hierarchical clustering analysis of top 100 DElncRNAs between S and normal samples (A), SD and normal samples (B). 
Row and column represents DElncRNAs and samples, respectively. JJ — S group; JT — SD group
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group, including LOC105369772-KIR2DS4 and C4BPA, 
LOC105378122-KIR3DL2 and LOC100499194- CD79A. 
Functional analysis of DEmRNAs  
and lncRNA-mRNA co-expression pairs  
Top 20 clusters by GO analysis of DEmRNAs in the S 
vs. N group, SD vs. N group, and S vs. SD group are 
shown in Figure 2. Key DEmRNAs in the S vs. N group 
were significantly enriched in the following: peptide 
chain elongation (p = 1.50713E-17), defence response 
to other organisms (p = 5.96629E-16), and cytokine 
signalling in the immune system (p = 7.44435E-15), 
while key DEmRNAs in the SD vs. N group were 
significantly enriched in the following: adaptive im-
mune system (p = 1.20789E-18), regulated exocytosis 
(p = 6.52941E-18), and formation of a pool of free 40S 
subunits (p = 7.85923E-14). The overlapping DEm-
RNAs in the S vs. N and SD vs. N group were enriched 
in the following: defence response to other organ-
isms (p = 4.37832E-14), immune regulatory interac-
tions between a lymphoid and a non-lymphoid cell 
(p = 4.46184E-10) and cell killing (p = 9.26847E-09). 
DEmRNAs in the SD vs. S group were significantly 
enriched in the following: eukaryotic translation elon-
gation (p = 1.94389E-22), myeloid cell differentiation 
(p = 2.18517E-16), and cellular protein catabolic process 
(p = 3.30271E-14). 
Differentially expressed genes in the S vs. N group 
were clustered into 19 pathways by KEGG analysis 
(Fig.  3A). Ribosome pathway (p = 1.52651E-12) en-
riched most genes. Differentially expressed genes 
in the SD vs. N group were clustered into 54 path-
ways (Fig.  3B). Among them, pathways in cancer 
(p = 0.00176), NOD-like receptor signalling pathway 
(p = 2.51189E-07), and influenza A (p = 3.98107E-07) en-
riched most genes. Overlapping DEmRNAs in the S vs. N 
and SD vs. N group were enriched in the following: nat-
ural killer cell-mediated cytotoxicity (p = 6.30957E-09), 
graft-versus-host disease (p = 6.30957E-07), and antigen 
processing and presentation (p = 1.99526E-06) (Fig. 3C). 
Differentially expressed genes in the SD vs. S group 
were enriched in 34 pathways, among which, DEm-
RNAs in the SD vs. S group were significantly enriched 
in the following: ribosome (p = 1E-14), HTLV-I infection 
(p = 0.000316228), and transcriptional misregulation in 
cancer (p = 5.01187E-06) (Fig. 3D).
In addition, the top 20 clusters by GO analysis of DEm-
RNAs of co-expressed DElncRNAs in the S vs. N group, 
SD vs. N group are shown in Figure 4. In GO analysis, 
co-expressed DEmRNAs of DElncRNAs in the S vs. N 
group were significantly enriched in the following: cyto-
kine signalling in the immune system (p = 1.39147E-11), 
peptide chain elongation (p = 4.01217E-11), and 
response to virus (p = 3.08943E-10). In the SD vs. N 
group, co-expressed DEmRNAs of DElncRNAs were 
significantly enriched in the following: adaptive im-
mune response (p = 3.01114E-16), regulated exocy-
tosis (p = 3.38002E-16), and platelet degranulation 
(p = 3.22747E-11). In KEGG analysis, co-expressed 
DEmRNAs of DElncRNAs were enriched into 12 and 48 
pathways in S vs. N and SD vs. N, respectively (Fig. 5). 
Discussion
Key genes were identified in the top 20 differentially 
expressed mRNAs and lncRNAs in all groups (S vs. N, 
Table 8. Significantly differentially expressed lncRNAs in SD vs. S group
Gene Locus Log2 (fold change) p value Up/Down
PSMD5-AS1 chr9:120843041-120854373 0.992632 0.0003 Up
LOC729737 chr1:91168-267354 1.30899 5.00E-05 Up
LOC105378415 chr10:88061829-88104391 0.702821 0.0009 Up
LOC105374150 chr3:148439991-148465791 1.67017 0.00045 Up
LOC105372321 chr19:21444103-21464331 1.73257 0.0001 Up
LOC105369735 chr12:40207309-40211449 1.48402 0.00065 Up
LOC105369319 chr11:60159240-60164400 1.17253 0.0011 Up
LOC105369219 chr20:1692887-1727569 1.36886 0.00105 Up
LOC101929638 chr22:29180622-29205834 1.75921 0.0011 Up
LOC101929007 chr19:21569901-21627976 1.38662 5.00E-05 Up
LOC101928214 chr2:87659750-87687161 1.12687 0.00035 Up
LINC01002 chr19:197015-202209 1.04842 5.00E-05 Up
JHDM1D-AS1 chr7:140177260-140179640 1.17132 5.00E-05 Up
LOC105377782 chr8:2199669-2206204 –1.4337 0.0011 Down
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Table 9. Classification of DEmRNAs in all groups
Gene name Shared genes p value  in SD vs. S Up/Down
p value  
in S vs. N Up/Down
p value  
in SD vs. N Up/Down
Shared genes that showed no different expression in SD vs. S
ARHGEF10 Yes 1 Down 5.00E-05 Down 5.00E-05 Down
IFI6 Yes 0.30125 Up 0.00335 Up 5.00E-05 Up
IFIT1 Yes 0.47405 Up 0.0002 Up 5.00E-05 Up
KIR2DS4 Yes 0.8401 Down 5.00E-05 Down 5.00E-05 Down
KIR3DL1 Yes 0.8715 Down 5.00E-05 Down 5.00E-05 Down
KIR3DL2 Yes 0.0916 Down 5.00E-05 Down 5.00E-05 Down
RAP1GAP Yes 0.3273 Down 5.00E-05 Down 5.00E-05 Down
KIR2DL1 Yes 0.75155 Down 5.00E-05 Down 0.0001 Down
KIR2DL3 Yes 0.51745 Down 5.00E-05 Down 0.00225 Down
Shared genes that showed different expression in SD vs. S
HDC yes 5.00E-05 Up 5.00E-05 Down 0.02025 Up
BATF2 Yes 5.00E-05 Up 5.00E-05 Down 0.0005 Up
ANK1 yes 5.00E-05 Up 0.0221 Up 5.00E-05 Up
LAIR2 No 5.00E-05 Down 5.00E-05 Up 0.5574 /
RPL26 No 5.00E-05 Down 5.00E-05 Up 0.40125 /
RPS3A No 5.00E-05 Down 5.00E-05 Up 0.46395 /
Different genes expression in S vs. N and SD vs. N group
SH2D1B No 5.00E-05 Down 5.00E-05 Up 0.6478 /
FCGBP No 0.0001 Down 5.00E-05 Up 0.8163 /
RPL39 No 0.0001 Down 5.00E-05 Up 0.51845 /
RPL23 No 0.0002 Down 5.00E-05 Up 0.1052 /
SLC2A14 No 5.00E-05 Up 5.00E-05 Down 0.88125 /
GATA2 No 5.00E-05 Up 5.00E-05 Down 0.52595 /
GPR162 No 5.00E-05 Down 0.30595 / 5.00E-05 Down
Different genes expression in SD vs. S and SD vs. N
ZNF683 No 5.00E-05 Down 0.23495 / 5.00E-05 Down
TCL1A No 5.00E-05 Down 0.08845 / 5.00E-05 Down
RPS26 No 5.00E-05 Down 0.00565 Up 5.00E-05 Down
RPS28 No 5.00E-05 Down 0.5493 / 0.00015 Down
ANKRD22 No 5.00E-05 Up 1 / 5.00E-05 Up
APOL4 No 5.00E-05 Up 1 / 5.00E-05 Up
FAM46C No 5.00E-05 Up 0.41555 / 5.00E-05 Up
PNMA6A NO 5.00E-05 Up 1 / 0.00045 Up
Table 10. Nearby mRNAs of DElncRNAs in S vs. N and SD vs. N
lncRNA mRNA
Chr Symbol Start-100kb End+100kb Symbol Start End
S vs. N
chr6 LOC105378122 167111706 167139241 CCR6 167111806 167139141
chr6 LOC102725068 31479817 31494894 MICB 31494880 31511124
SD vs. N
chr9 LOC105376032 36833173 37036049 PAX5 36833273 37035949
chr12 LOC101928100 10363668 10410246 KLRK1 10363768 10410146
chr1 LOC105371464 159800380 159816357 FCRL6 159800480 159816257
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SD vs. N and S vs. SD). Among these genes, several 
genes were deduced to be involved in SCH, including 
LAIR2, PNMA6A, SFRP2, RAP1GAP, BATF2, and ln-
cRNA- PAX8-AS1. According to previous studies, LAIR2 
was increased in patients with autoimmune thyroid 
diseases while PNMA6A was verified to decrease in 
hypothyroid [15, 16]. SFRP2 was a target of thyroid 
hormone receptor alpha1 [17], and RAP1GAP might 
function in thyroid cancer [18]. Notably, PAX8 was 
regarded a transcription factor in the developing and 
adult thyroid [19]. PAX8-AS1 was an antisense RNA to 
regulate PAX8, which was reported to inhibit cell cycle 
in vitro and associate with thyroid cancer [20, 21]. 
We assumed shared genes that showed coincident 
expression in the S and SD group were involved in 
SCH. In previous studies, ARHGEF10 was reported to 
be involved in atherosclerosis and hypertriglyceridae-
mia, both of which complicated with diabetes [22, 23]. 
IFI6 and IFIT1 were reported to be highly expressed in 
diabetes [24]. KIR3DL2, KIR2DL1, KIR3DL3, KIR2DS4, 
and KIR3DL1 belong to killer cell immunoglobulin-like 
receptors, which have been associated with diabetes 
[25]. A published study proposed that the genetic imbal-
ance between KIRs and their HLA class 1 ligands might 
contribute to the pathogenesis of diabetes [26]. Notably, 
KIR3DL1 was co-expressed with PAX8-AS1 in our study. 
Figure 4. DElncRNA-DEmRNA co-expression network of S vs. N group (A), in SD vs. N group (B). The triangle and the circle 
represent DElncRNAs and DEmRNAs, respectively. Green and red colours represent down-regulation and up-regulation, respectively. 
The top10 down-/up-regulated DEmRNAs and DElncRNAs are represented with the black border
A B
Figure 5. Top 20 significantly enriched GO terms in S vs. N group (A), SD vs. N group (B), overlapping DEmRNAs in S and SD 
(C), SD vs. S group (D). The Y-axis shows the description of GO terms and the X-axis represents p value. The colour scale represents 
counts of DEmRNAs  
A B
C D
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In addition, combining with functional enrichment 
analyses, pathways of shared genes (KIR3DL1) in both S 
vs. N group and SD vs. N group enriched were involved 
in type 2 diabetes, including natural killer cell-mediated 
cytotoxicity [27] and antigen processing and presenta-
tion [28]. Natural killer cells (a subset of lymphocytes) 
contribute to innate immunity. It is found that natural 
killer cell-mediated cytotoxicity is associated with both 
anti-thyroid peroxidase antibody and type 2 diabetes 
[27, 29]. In addition, those genes involved in antigen 
processing and presentation are related to anti-thyroid 
peroxidase antibody and type 2 diabetes [29, 30]. There-
fore, we deduced that the prevalence of type 2 diabetes 
might be associated with subclinical hypothyroidism, 
and the regulation of PAX-AS1 on KIR3DL1 might func-
tion in this process. To explore whether high occurrence 
of type 2 diabetes existed in patients with subclinical 
hypothyroidism, we focused on genes that showed 
significantly different expression between the S and SD 
group. ANK1 showed significantly higher expression 
in the SD group than in the S and normal group, which 
is in accordance with previous report that high expres-
sion might contribute to type 2 diabetes susceptibility 
[31]. Conversely, APOL4, FAM46C and GPR162 showed 
Figure 6. KEGG pathways in S vs. N group (A), SD vs. N (B), overlapping DEmRNAs in S and SD (C), in SD vs. S group (D). 
The Y-axis shows KEGG pathways and the X-axis represents rich factor to show enrichment degree. The colour scale represents –log 
(p-value), and the area scale represents counts of DEmRNAs
A B
C D
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significantly different expression between SD and S 
group but showed no difference in expression between 
the S and the normal group. According to the literature, 
APOL4 was reported to have a significant correlation 
with type 2 diabetes with hypertriglyceridaemia [32]. 
FAM46C was verified to highly express in both type 1 
and type 2 diabetes [33]. GPR162 was proven as a re-
ceptor to be involved in the development of diabetes 
complications according to research in diabetic rats [34, 
35]. The expression patterns of the above five genes were 
consistent with those in the literature about diabetes. Al-
though the functional analysis of DEmRNAs in the SD 
vs. S group was performed, the regulatory pathway of 
type 2 diabetes in patients with SCH remained uncertain. 
Fortunately, key lncRNA was identified in the SD vs. S 
group. JHDM1D-AS1, as antisense RNA of JHDM1D, 
was involved in cancers by promoting angiogenesis and 
causing inflammation [36]. Moreover, JHDM1D belonged 
to histone demethylase as well as being homologous with 
JHDM2a. The loss of function of JHDM2a was verified 
to function in obesity and metabolic syndrome in a prior 
study in rats [37]. In our study, the up-regulation of 
JHDM1D-AS1 in the SD group might cause inflammation 
and metabolic syndrome. In addition, our study revealed 
that JHDM1D-AS1 was co-expressed with ANK1. We 
deduced that JHDM1D-AS1 regulated ANK1 epigenetics 
mechanisms to promote the occurrence of type 2 diabe-
tes. However, several genes showed confusing expres-
sion patterns, which were up- or down-regulated in 
S vs. N but showed no difference between SD vs. N, 
including up-regulated genes SH2D1B and ZNF683, 
and down-regulated genes SLC2A14. Therefore, more 
molecules like miRNAs and more samples should be ex-
cavated, and biology experiments should be performed 
to explore the molecular mechanism in SCH complicated 
with type 2 diabetes.
Conclusion
Several genes were deduced to function in SCH, includ-
ing LAIR2, PNMA6A, SFRP2, and lncRNA-PAX8-AS1, 
and we identified ANK1 and its co-expressed ln-
Figure 7. Top 20 significantly enriched GO terms of DEmRNA-DElncRNAs in S vs. N group (A), SD vs. N group (B). The Y-axis 
shows the description of GO terms and the X-axis represents p value. The colour scale represents counts of DEmRNA-DElncRNAs
A
B
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cRNA-JHDM1D-AS1, which were deduced to function 
in SCH complicated with type 2 diabetes. The research 
initially proposed the theory that patients with SCH 
might have a higher risk of type 2 diabetes, and it pro-
vides a basis for further investigation of SCH compli-
cated with type 2 diabetes. Our study suggested that mo-
lecular changes in identified lncRNAs and mRNAs may 
provide a novel clue in understanding the pathology 
of SCH and SCH complicated with diabetes. However, 
there are limitations to our study. Firstly, the sample size 
is small. Large numbers of blood samples of S, SD, and N 
are further needed. Secondly, the potential mechanism 
of identified lncRNAs and mRNAs was not investigated. 
Some in vivo or in vitro experiments are also needed 
to explore the biological function mechanism of identi-
fied molecules. Thirdly, it would be very interesting to 
add more information to the research and perform the 
same transcriptome analysis in patients with type 2 
diabetes and compare this analysis with the described 
results. Further research is needed.
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